Limits...
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease.

Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS, Alzheimer's Disease Cooperative Stu - Neurology (2015)

Bottom Line: Resveratrol was safe and well-tolerated.Resveratrol and its major metabolites penetrated the blood-brain barrier to have CNS effects.This study provides Class II evidence that for patients with AD resveratrol is safe, well-tolerated, and alters some AD biomarker trajectories.

View Article: PubMed Central - PubMed

Affiliation: From the Department of Neurology (R.S.T., B.A.R.), Georgetown University, Washington, DC; the Department of Neurosciences (R.G.T., J.B.B., R.A.R., R.R., P.S.A.), University of California, San Diego, La Jolla; the Department of Internal Medicine (S.C.), Wake Forest University, Winston-Salem, NC; the Departments of Psychiatry, Neurology, and Neurobiology (C.H.v.D.), Yale University, New Haven, CT; and the Clinical Biotechnology Research Institute (J.M.), Roper St. Francis Healthcare, Charleston, SC. rst36@georgetown.edu.

No MeSH data available.


Related in: MedlinePlus

Flow diagram and disposition of the treatment groupsMMSE = Mini-Mental State Examination.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4626244&req=5

Figure 1: Flow diagram and disposition of the treatment groupsMMSE = Mini-Mental State Examination.

Mentions: A total of 179 participants were screened, of whom 60 were not randomized (50 screen-failed and 10 withdrew consent). Participants (119) were randomized as shown (figure 1). A total of 104 completed the study (12.6% dropout), and 77 completed 2 CSF collections (34% dropout). Eighteen participants discontinued treatment early and 15 discontinued the study. The population was English-speaking, 57% female, and 91% Caucasian. The baseline characteristics revealed that the placebo group had a longer AD duration (measured from year of symptom onset) (table 1). Results must be interpreted with caution given this caveat. However, a post hoc exploratory analysis found no difference between groups when AD duration was measured in years from diagnosis, and a post hoc re-analysis adjusting for age and AD duration in the MMRM model did not alter results, with the exception that difference in ventricular volume became nonsignificant (p = 0.10) (appendix e-1 on the Neurology® Web site at Neurology.org).


A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease.

Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS, Alzheimer's Disease Cooperative Stu - Neurology (2015)

Flow diagram and disposition of the treatment groupsMMSE = Mini-Mental State Examination.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4626244&req=5

Figure 1: Flow diagram and disposition of the treatment groupsMMSE = Mini-Mental State Examination.
Mentions: A total of 179 participants were screened, of whom 60 were not randomized (50 screen-failed and 10 withdrew consent). Participants (119) were randomized as shown (figure 1). A total of 104 completed the study (12.6% dropout), and 77 completed 2 CSF collections (34% dropout). Eighteen participants discontinued treatment early and 15 discontinued the study. The population was English-speaking, 57% female, and 91% Caucasian. The baseline characteristics revealed that the placebo group had a longer AD duration (measured from year of symptom onset) (table 1). Results must be interpreted with caution given this caveat. However, a post hoc exploratory analysis found no difference between groups when AD duration was measured in years from diagnosis, and a post hoc re-analysis adjusting for age and AD duration in the MMRM model did not alter results, with the exception that difference in ventricular volume became nonsignificant (p = 0.10) (appendix e-1 on the Neurology® Web site at Neurology.org).

Bottom Line: Resveratrol was safe and well-tolerated.Resveratrol and its major metabolites penetrated the blood-brain barrier to have CNS effects.This study provides Class II evidence that for patients with AD resveratrol is safe, well-tolerated, and alters some AD biomarker trajectories.

View Article: PubMed Central - PubMed

Affiliation: From the Department of Neurology (R.S.T., B.A.R.), Georgetown University, Washington, DC; the Department of Neurosciences (R.G.T., J.B.B., R.A.R., R.R., P.S.A.), University of California, San Diego, La Jolla; the Department of Internal Medicine (S.C.), Wake Forest University, Winston-Salem, NC; the Departments of Psychiatry, Neurology, and Neurobiology (C.H.v.D.), Yale University, New Haven, CT; and the Clinical Biotechnology Research Institute (J.M.), Roper St. Francis Healthcare, Charleston, SC. rst36@georgetown.edu.

No MeSH data available.


Related in: MedlinePlus